Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a diabetes drug shield Kids' kidneys?

NCT ID NCT07204743

Disease control Sponsor: Al-Quds University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether dapagliflozin, a drug used in adults for diabetes and kidney protection, can reduce protein leakage in the urine of children with chronic kidney disease. Ten children aged 4 to 18 with persistent proteinuria despite standard therapy will take the drug, and researchers will measure changes in urine protein and kidney function. The goal is to see if the drug can help control the disease and slow kidney damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

4 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pediatric patients aged 4-18 years * Persistent proteinuria \> 500 mg/day despite standard therapy. * Stable renal function (eGFR ≥ 30 mL/min/1.73 m²). * Ability to comply with follow-up visits and study procedures. * Written informed consent obtained from parents or legal guardians, and assent from the patient when appropriate. Exclusion Criteria: * Known hypersensitivity or contraindication to dapagliflozin or other SGLT2 inhibitors. * Severe renal impairment (eGFR \< 30 mL/min/1.73 m²) or end-stage renal disease requiring dialysis. * Active urinary tract infection, severe dehydration, or hypotension. * Participation in another clinical trial within the last 30 days. * Any comorbid condition or medical history that, in the investigator's opinion, would interfere with study participation or interpretation of results.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dapagliflozin (forxiga) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

kidney disorder proteinuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dapagliflozin (forxiga) Pediatric kidney disease Proteinuric diseases SGLT 2 inhibitors

Contacts and locations

Locations

  • Al Ahli hospital

    Hebron, Palestine, P700, Palestinian Territories

More trials for these conditions

Other studies related to the condition(s) this trial covers.